Trial Profile
Predictive TP53 mutational biomarker of pazopanib response in advanced sarcomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Sarcoma
- Focus Biomarker; Therapeutic Use
- 17 Dec 2015 New trial record
- 08 Dec 2015 Results published in the Annals of Oncology